124 related articles for article (PubMed ID: 7805042)
1. Development of a humanized disulfide-stabilized anti-p185HER2 Fv-beta-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug.
Rodrigues ML; Presta LG; Kotts CE; Wirth C; Mordenti J; Osaka G; Wong WL; Nuijens A; Blackburn B; Carter P
Cancer Res; 1995 Jan; 55(1):63-70. PubMed ID: 7805042
[TBL] [Abstract][Full Text] [Related]
2. Construction, expression, and activities of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation.
Siemers NO; Kerr DE; Yarnold S; Stebbins MR; Vrudhula VM; Hellström I; Hellström KE; Senter PD
Bioconjug Chem; 1997; 8(4):510-9. PubMed ID: 9258449
[TBL] [Abstract][Full Text] [Related]
3. Improved yield and stability of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation, by protein engineering.
McDonagh CF; Beam KS; Wu GJ; Chen JH; Chace DF; Senter PD; Francisco JA
Bioconjug Chem; 2003; 14(5):860-9. PubMed ID: 13129388
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody beta-lactamase conjugates.
Svensson HP; Vrudhula VM; Emswiler JE; MacMaster JF; Cosand WL; Senter PD; Wallace PM
Cancer Res; 1995 Jun; 55(11):2357-65. PubMed ID: 7757987
[TBL] [Abstract][Full Text] [Related]
5. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy.
Florent JC; Dong X; Gaudel G; Mitaku S; Monneret C; Gesson JP; Jacquesy JC; Mondon M; Renoux B; Andrianomenjanahary S; Michel S; Koch M; Tillequin F; Gerken M; Czech J; Straub R; Bosslet K
J Med Chem; 1998 Sep; 41(19):3572-81. PubMed ID: 9733483
[TBL] [Abstract][Full Text] [Related]
6. Tumor-selective prodrug activation by fusion protein-mediated catalysis.
Bosslet K; Czech J; Hoffmann D
Cancer Res; 1994 Apr; 54(8):2151-9. PubMed ID: 8174122
[TBL] [Abstract][Full Text] [Related]
7. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth.
Sarup JC; Johnson RM; King KL; Fendly BM; Lipari MT; Napier MA; Ullrich A; Shepard HM
Growth Regul; 1991 Jun; 1(2):72-82. PubMed ID: 1688187
[TBL] [Abstract][Full Text] [Related]
8. Genetic construction, expression, and characterization of a single chain anti-carcinoma antibody fused to beta-lactamase.
Goshorn SC; Svensson HP; Kerr DE; Somerville JE; Senter PD; Fell HP
Cancer Res; 1993 May; 53(9):2123-7. PubMed ID: 8481914
[TBL] [Abstract][Full Text] [Related]
9. Construction, expression and characterization of the engineered antibody against tumor surface antigen, p185(c-erbB-2).
Cheng LS; Liu AP; Yang JH; Dong YQ; Li LW; Wang J; Wang CC; Liu J
Cell Res; 2003 Feb; 13(1):35-48. PubMed ID: 12643348
[TBL] [Abstract][Full Text] [Related]
10. Regressions and cures of melanoma xenografts following treatment with monoclonal antibody beta-lactamase conjugates in combination with anticancer prodrugs.
Kerr DE; Schreiber GJ; Vrudhula VM; Svensson HP; Hellström I; Hellström KE; Senter PD
Cancer Res; 1995 Aug; 55(16):3558-63. PubMed ID: 7627964
[TBL] [Abstract][Full Text] [Related]
11. Engineering Fab' fragments for efficient F(ab)2 formation in Escherichia coli and for improved in vivo stability.
Rodrigues ML; Snedecor B; Chen C; Wong WL; Garg S; Blank GS; Maneval D; Carter P
J Immunol; 1993 Dec; 151(12):6954-61. PubMed ID: 7903100
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.
Pietras RJ; Poen JC; Gallardo D; Wongvipat PN; Lee HJ; Slamon DJ
Cancer Res; 1999 Mar; 59(6):1347-55. PubMed ID: 10096569
[TBL] [Abstract][Full Text] [Related]
13. Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments.
Reiter Y; Brinkmann U; Lee B; Pastan I
Nat Biotechnol; 1996 Oct; 14(10):1239-45. PubMed ID: 9631086
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic and antitumor activity of a recombinant tumor necrosis factor-B1(Fv) fusion protein on LeY antigen-expressing human cancer cells.
Scherf U; Benhar I; Webber KO; Pastan I; Brinkmann U
Clin Cancer Res; 1996 Sep; 2(9):1523-31. PubMed ID: 9816329
[TBL] [Abstract][Full Text] [Related]
15. Rapid and specific uptake of anti-Tac disulfide-stabilized Fv by interleukin-2 receptor-bearing tumors.
Webber KO; Kreitman RJ; Pastan I
Cancer Res; 1995 Jan; 55(2):318-23. PubMed ID: 7812965
[TBL] [Abstract][Full Text] [Related]
16. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic effects of monoclonal antibody-beta-lactamase conjugates in combination with a nitrogen mustard anticancer prodrug in models of human renal cell carcinoma.
Svensson HP; Frank IS; Berry KK; Senter PD
J Med Chem; 1998 Apr; 41(9):1507-12. PubMed ID: 9554883
[TBL] [Abstract][Full Text] [Related]
18. Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins.
Reiter Y; Pastan I
Clin Cancer Res; 1996 Feb; 2(2):245-52. PubMed ID: 9816166
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and antitumor activity of a bivalent disulfide-stabilized Fv immunotoxin with improved antigen binding to erbB2.
Bera TK; Viner J; Brinkmann E; Pastan I
Cancer Res; 1999 Aug; 59(16):4018-22. PubMed ID: 10463601
[TBL] [Abstract][Full Text] [Related]
20. Site-specific prodrug activation by antibody-beta-lactamase conjugates: regression and long-term growth inhibition of human colon carcinoma xenograft models.
Meyer DL; Jungheim LN; Law KL; Mikolajczyk SD; Shepherd TA; Mackensen DG; Briggs SL; Starling JJ
Cancer Res; 1993 Sep; 53(17):3956-63. PubMed ID: 8358723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
